Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial.

First-line pumitamig plus nab-paclitaxel in advanced or metastatic triple-negative breast cancer achieved a confirmed objective response rate of 73·8% (31/42).

• Why it matters: Triple-negative breast cancer needs safer, more effective first-line options, and pumitamig’s dual targeting of PD-L1 and VEGFA requires validation with standard chemotherapy in this setting.
• What they did: In a single-arm phase 1b/2 trial in China, 42 Chinese female patients received pumitamig 20 mg/kg every 2 weeks plus nab-paclitaxel 100 mg/m² on days 1, 8, and 15 of 28-day cycles, with response assessed using RECIST v1.1.
• The result: Grade 3+ treatment-related events included decreased neutrophil count (31%), decreased white blood cell count (26%), proteinuria (14%), and febrile neutropenia (12%), with no treatment-related deaths and treatment discontinuation due to adverse events in 10% overall.

AI summary of the abstract · may contain errors · not medical advice · read the paper.